NRx Pharmaceuticals (NASDAQ:NRXP) Earns Buy Rating from D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $31.00 target price on the stock.

Several other analysts have also weighed in on NRXP. Ascendiant Capital Markets lifted their target price on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. HC Wainwright reissued a “buy” rating and set a $19.00 price target on shares of NRx Pharmaceuticals in a report on Monday, November 25th. Finally, EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 21st.

NRx Pharmaceuticals Stock Up 43.8 %

NRx Pharmaceuticals stock opened at $2.20 on Tuesday. NRx Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $7.33. The stock has a market cap of $26.61 million, a price-to-earnings ratio of -1.03 and a beta of 1.25. The business has a 50 day moving average price of $1.33 and a two-hundred day moving average price of $1.76.

Insider Activity at NRx Pharmaceuticals

In other news, Chairman Jonathan C. Javitt purchased 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The shares were acquired at an average price of $1.17 per share, for a total transaction of $46,800.00. Following the completion of the acquisition, the chairman now directly owns 84,634 shares in the company, valued at approximately $99,021.78. The trade was a 89.62 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 19.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Anson Funds Management LP acquired a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 142,525 shares of the company’s stock, valued at approximately $241,000. Anson Funds Management LP owned 1.33% of NRx Pharmaceuticals at the end of the most recent reporting period. 4.27% of the stock is owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.